Trial Profile
An Early Access Program (EAP) for Ibrutinib (PCI-32765) in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions; Expanded access
- Sponsors Janssen-Cilag
- 17 Mar 2017 Status changed from recruiting to completed.
- 12 May 2015 New trial record